Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, Parkinson
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.Patients showed a statistically significant improvement when two fixed doses of the drug,
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.
AbbVie Parkinson’s drug helps improve symptoms in late-stage study
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.
AbbVie’s Parkinson’s Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three years.
3h
AbbVie: Dividend Discount Model Suggests Large Valuation Risks
AbbVie faces growth challenges with mixed Q2 results. Click here for a full investment analysis of ABBV stock.
3h
Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 78% Impressive?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...
BioSpace
2d
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...
Daily
7h
AbbVie seeks USFDA accelerated approval for telisotuzumab vedotin for previously treated non small cell lung cancer
AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
2d
AbbVie Inc. stock rises Thursday, still underperforms market
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
1d
AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer
AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...
2d
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...
1d
on MSN
Final Trades: Meta, Accenture, Abbvie and Disney
Maggie Smith, acting legend of 'Harry Potter' and 'Downton Abbey' fame, dies at 89 Aerial footage shows extensive Helene ...
3d
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
2d
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Parkinson
Dow Jones Industrial Average
Food and Drug Administration
tavapadon
New York Stock Exchange
Feedback